Press Releases

11.11.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.10.2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

11.04.2022

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

11.03.2022

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

11.01.2022

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

11.01.2022

Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate

10.18.2022

Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

10.13.2022

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

10.12.2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

10.05.2022

Pfizer Completes Acquisition of Global Blood Therapeutics 

10.04.2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

10.03.2022

Pfizer Completes Acquisition of Biohaven Pharmaceuticals